ClinicalTrials.gg
Not yet recruitingNCT07036471myCare Start-IUpdated Jun 25, 2025

Supporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland

An interventional study of myCare Start in Cardio-vascular Disease, Depression Disorders and Diabetes, sponsored by University of Geneva, Switzerland. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by University of Geneva, Switzerland · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Diabetes Mellitus with a site in Switzerland — 9 open to participants now, 11 under way, none of them phase 3. Diabetes Mellitus · Switzerland.

Planned enrollment
4th of 63
1,600 · median 141
Started
2025
with 2 others
No phase
31 of 87
4 open now
Primary completion
2027-01
later than 5 of 10 live
Registered
86th of 87
by date

Among the 87 studies in Diabetes Mellitus with a site in Switzerland, this one is the 4th largest by planned enrollment of the 63 interventional ones that give a count, is one of 3 that started in 2025, is one of 31 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 86th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

9 of the 87 studies in Diabetes Mellitus with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Diabetes Mellitus with a site in Switzerland, or all of them as a file.
02

Study summary

In Phase B, the aim is to evaluate the myCare Start service in routine care within the ambulatory primary care medicine and community pharmacy setting in Switzerland. A Type II hybrid effectiveness-implementation study will be conducted to evaluate the effectiveness (improvement in adherence), cost-effectiveness and implementation of the service. This evaluation will allow us to build the necessary contextual relevant evidence base to support sustainable funding of the service in the long term.

Read the detailed description

In Switzerland, almost half of the population has a long-term condition. Non-adherence to essential medication to treat these long-term conditions leads to suboptimal patient outcomes, increased hospitalisations, mortality, and financial burden to patients and healthcare systems. Innovative ways to address patient adherence within the ambulatory primary care medicine and community pharmacy setting in Switzerland are needed. Based on the UK New Medicine Service (NMS), pharmaSuisse introduced myCare Start into community pharmacy practice in Switzerland. However, like in other international settings barriers were experienced limiting its uptake and impact highlighting the need for context-based adaptation when the service is implemented in new settings. The myCare Start Implementation project (myCare Start-I) is a biphasic project to assist in optimising fit of the myCare Start service for Switzerland (Phase A) and evaluate its impact (Phase B). In Phase A, which is now complete, using implementation science methods, researchers conducted a thorough contextual analysis of the Swiss primary care ecosystem and adapted the existing myCare Start model using an iterative co-creation process with stakeholders to suit the needs of the primary care context. In Phase B a Type II hybrid effectiveness-implementation study will be conducted to evaluate the effectiveness (improvement in adherence), cost-effectiveness and implementation of the service to build the necessary evidence base to support sustainable funding of the service in the long term.

03

Conditions studied

  • Cardio-vascular Disease
  • Depression Disorders
  • Diabetes
  • COPD
  • Asthma Bronchiale
  • Hyperlipidaemia
  • Medication Initiation for Long-term Conditions

Keywords

  • patient adherence
  • medication adherence
  • medication initiation
  • long-term treatment
  • implementation science
  • interprofessional collaboration
  • outpatient care
  • community pharmacy
  • general practitioner
  • cost-effectiveness
  • medication adherence support programme
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients

Inclusion Criteria:

  • Must have mandatory basic health insurance in Switzerland
  • Must have been newly prescribed one or more new long-term medications in accordance with the following chronic conditions: cadisovascular diseases (incl. hyertension and thromboprophylaxis), diabetes, hyperlipidemia, depression, respiratory illness (asthma and )
  • Must be able to self-manage treatment (i.e. they live at home without any support to manage their medication, exception: patient uses a pill dispenser and fills it in by him-/herself)
  • Must be able to understand language spoken by pharmacy staff and can read and understand study documents (French, German, English)
  • Must understand and are willing to consent to the myCare Start-I study (including the agreement on self-reported questionnaires and collection of health care data via their health insurance company)
  • in the intervention arm, patients must receive the myCare Start service

For this study, a new medication is a medication that has not been previously dispensed to the patient. This includes one or more new medications for a new diagnosis and or new medications for pre-existing diagnosis of a long-term condition. Included in this working definition:

  • The new medication is indicated for one of the five long-term diseases listed above
  • Patient has never had this active ingredient dispensed before (patient still considered eligible if they have received a small initial sample pack from their physician) or restarts an active ingredient after a period of interruption of at least 12 months (time period to be reported by the patient). Please note that for patients, that have already started a sample pack of medication the myCare Start Consultation One can start upon first dispensation at the pharmacy, there is no need to wait 7-14 days.
  • The new active ingredient can be part of a combo preparation (e.g. a diuretic added to an ACE inhibitor into the same preparation)
  • Patient has had no change in active ingredient but has an important change in treatment administration, such as:

    • Change of galenic form (e.g. two different types of inhalators for asthma/COPD)
    • Intensification of dosage regiment (e.g. twice a day instead of once a day)
  • The following change is not considered as medication initiation:

    • New dosage of already known active ingredient (e.g. dose escalation of antidepressants)
    • Simplification of administration mode (e.g. metformin 1000 mg 1-0-0 instead of 500 mg 1-0-1; change in antihypertensive drug regiment in elderly patients having vertigo in the morning: 0-0-X instead of X-0-0)

Exclusion Criteria:

  • Patients participating or having participated in an education program about their disease or treatment in the last 3 months, led by healthcare providers such as physicians, nurses, pharmacists or other (e.g. education provided by nurses for type I diabetes patients)

Physicians:

Inclusion criteria

- Any physician treating a patient for one of the five long-term illnesses listed above is eligible to refer the patient to a pharmacy providing myCare start.

Pharmacies:

Inclusion criteria:

  • Have to be enrolled into the myCare Start service and comply to the requirements of the pharmacy quality system management of having access to a private consultation room or area
  • Must agree to participate in the research study, including the recruitment of control patients and the delivery of the myCare Start service to intervention patients.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,600 participants (estimated)

Study arms

  • No intervention
    Usual Care Arm

    In the Usual Care Arm, the patients will receive the usual care from their pharmacist after being prescribed a new long-term medication.

  • Experimental
    myCare Start Arm

    In the myCare Start Arm, the patients will receive the myCare Start service in their pharmacy after being prescribed a new long-term medication. myCare Start is an interprofessional health service offered by community pharmacies in Switzerland to support medication adherence in patients starting a new long-term treatment. It consists of two 10-minute, semi-structured and tailored consultations delivered by community pharmacists during the first 6 weeks of a patient initiating a new long-term medication, followed by tailored feedback to the patient's physician.

    Behavioral: myCare Start

Interventions

  • BehavioralmyCare Start

    The service consists of two 10-minute, semi-structured and tailored consultations delivered by community pharmacists during the first 6 weeks of a patient initiating a new long-term medication, followed by tailored feedback to the patient's physician.

06

What researchers measure

Primary outcomes

  1. Medication adherence (subjective measure)

    Patient self-reported (subjective measure): We will use the BAASIS© (Basel Assessment of Adherence to Immunosuppressive Medications Scale), a 6-item scale with demonstrated psychometric properties in transplantation and other chronic diseases, as it assesses adherence according to the ABC taxonomy (Initiation, Medication Implementation, and Persistence). The BAASIS scale has a minimum and maximum value of 6 and 30, respectively. Lower scores on the BAASIS indicate poorer adherence to immunosuppressive medications, while higher scores indicate better adherence. This self-report instrument consists of six items that assess different aspects of medication adherence, including dose taking, drug holidays, timing deviation, reduction of dose, persistence, and timing of dose taking.

    Time frame: Surveys at 14 days, 6 weeks, 3, 6 and12 months upon enrollement.

Secondary outcomes

  1. Medication adherence (objective measure)

    Prescription renewal records (objective measure): Medication renewal records will be extracted from health insurance data and analyzed using the "AdhereR" software in R.

    Time frame: Form 1 month prior to enrollement up to 12 months after enrollment of the patient in the study.

  2. Cost-effectiveness short-term

    Total healthcare utilisation, in terms of total costs per patient, will be evaluated over the duration of the myCare Start follow-up period (12 months) using health insurance data. This will be combined with adherence results to determine the incremental cost-effectiveness ratio between the total costs per patient in the intervention vs. the control groups and the difference in adherence between groups. The survey will be forwarded to the patient at 14 days, 6 months, and 12 months after inclusion into the study via an emailed online survey. The main analysis consists of calculating 1) the incremental cost-effectiveness ratio between the total costs per patient in the intervention vs. the control group and 2.) the difference in adherence between groups and the probability that the intervention is cost-effective when the willingness to pay varies (i.e. the cost-effectiveness acceptability curve), the two classic indicators of cost-effectiveness analyses of health programmes.

    Time frame: 12 months upon enrollment

  3. Cost-effectiveness long-term

    Long-term potential healthcare cost savings will be evaluated using Markov Modelling. The Markov Modelling approach applied in this study is an adapted version of the models previously used in the UK to evaluate the New Medicine Service, adjusted with parameters tailored to the Swiss context. This approach will enable the projection and estimation of medium- and long-term benefits arising from improved adherence to the prescriptions as a result of the myCare start intervention. In Switzerland, the most commonly prescribed medications for long-term illnesses include cholesterol-lowering therapies, type 2 diabetes drugs, hypertension treatments, and antidepressants. For these four medication groups, specific Markov models have been developed. These calculations will be conducted during the 12-month longitudinal follow-up phase.

    Time frame: Calculations will be conducted during the 12-month follow-up phase

  4. Implementation Outcome: Acceptability

    The AIM (=Acceptability of Intervention Measure) will be used.

    Time frame: - Every 2 months during the intervention phase of the study (for pharmacies and physicians) - at 2 & 6 weeks, 3, 6 and 12 months upon inclusion for intervention patient.

  5. Implementation Outcome: Appropriateness

    The IAM (=Intervention Appropriateness Measure) will be used.

    Time frame: - Every 2 months during the intervention phase of the study (for pharmacies and physicians) - at 2 & 6 weeks, 3, 6 and 12 months upon inclusion for intervention patient.

  6. Implementation Outcome: Feasibility

    The FIM (=Feasibility of Intervention Measure) will be used.

    Time frame: - Every 2 months during the intervention phase of the study (for pharmacies and physicians) - at 2 & 6 weeks, 3, 6 and 12 months upon inclusion for intervention patient.

  7. Implementation Outcomes: Implementation cost

    Cost of implementation will be assessed using the time-driven activity-based cost (TDABC) instrument. This pragmatic method allows investigators to systematically estimate the cost of implementation strategies (e.g. training, reorganisation of practice, regular stakeholder meetings) and the cost of the intervention.

    Time frame: Throughout the duration of the study - approximately 12 months

  8. Implementation Outcomes: Adoption

    Adoption is defined as "the intention, initial decision, or action to try or employ an innovation or evidence-based practice". It will be measured through investigator onboarding logs and consultation records (No. of invited pharmacies and physicians, No. who completed training, No. who recruited or referred patients, No. of patients who participated in the intervention).

    Time frame: Throughout the duration of the study - approximately 12 months

  9. Implementation Outcomes: Fidelity

    Fidelity is defined as the degree to which an intervention was implemented as it was prescribed in the original protocol. Consultation records (from the myCare Start consultations) and facilitation checklists will be used, to understand if the service is being carried out as intended and in appropriate areas.

    Time frame: During the intervention phase of the pharmacies - approximately 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — Once fully anonymized, quantitative data will be annotated and structured to make them sharable, and registered in a FAIR-compliant data repository.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Jan 2027, 19 months later.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 19 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
Jun 25, 2025
StartEst.
Jun 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07036471
Lead sponsor
University of Geneva, Switzerland
Collaborators
University of Basel, pharmaSuisse, Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland, University of Bern
Responsible party
Marie Paule Schneider, PhD (Prof. Dr. Marie Paule Schneider, University of Geneva, Switzerland) — Principal investigator
First posted
Jun 25, 2025
Start date
Jun 2025 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jun 25, 2025

Study contacts

Marie Paule Schneider, Prof. PhD
Contact
marie.schneider@unige.ch
+41 22 379 53 16
Sarah Serhal, PhD
Contact
sarah.serhal@unige.ch
+41 22 379 11 97
Marie Paule Schneider, Prof. PhD
principal investigator · Uinversity of Geneva

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion